Polo样激酶1是乙型肝炎病毒复制的促病毒宿主因子
研究在原发性人肝细胞、分化的HepaRG细胞及人源化肝脏FRG小鼠中证实,HBV感染激活细胞PLK1,药物抑制或siRNA敲低PLK1可抑制HBV DNA生物合成,而过表达组成性活化PLK1则增加其合成;BI-2536在体内强效抑制HBV感染,并鉴定HBV核心蛋白为PLK1底物。
要点
- HBV感染激活原代人肝细胞和分化HepaRG细胞中的PLK1。
- BI-2536或siRNA敲低PLK1抑制HBV DNA生物合成,过表达PLK1CA则增加。
- BI-2536在人源化肝脏FRG小鼠体内强效抑制HBV感染。
核心结论
- PLK1是促病毒宿主因子,可被视为抗病毒与抗肿瘤联合策略的靶点,用于对抗HBV感染及HBV介导的癌变。
研究设计与样本
- 研究采用原代人肝细胞和分化HepaRG细胞的HBV感染模型,结合药物性PLK1抑制剂、siRNA介导的敲低和组成性活化PLK1过表达。
- 使用人源化肝脏Fah-/-/Rag2-/-/Il2rg-/-(FRG)小鼠模型确定PLK1抑制剂BI-2536对HBV感染的体内抗病毒效果。
- 采用体外PLK1激酶实验和定点诱变证明HBV核心蛋白是PLK1底物。
主要发现
- HBV感染激活原代人肝细胞和分化HepaRG细胞中的细胞PLK1。
- BI-2536或siRNA介导的PLK1敲低抑制HBV DNA生物合成,而过表达PLK1CA增加其合成。
- 在感染HBV的人源化肝脏FRG小鼠中给予BI-2536强烈抑制HBV感染。
- BI-2536导致核衣壳细胞内形成/积累减少,PLK1的促病毒作用与核衣壳生物发生相关。
- 体外研究鉴定HBV核心蛋白为PLK1底物,并绘制了该蛋白上的PLK1磷酸化位点。
临床怎么用
- 作者认为PLK1可被视为抗病毒与抗肿瘤联合策略的靶点,用于对抗HBV感染及HBV介导的癌变。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Chronic hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC) and current treatments for chronic hepatitis B and HCC are suboptimal. Herein, we identified cellular serine/threonine Polo-like-kinase 1 (PLK1) as a positive effector of HBV replication. The aim of this study was to demonstrate the proviral role of PLK1 in HBV biosynthesis and validate PLK1 inhibition a potential antiviral strategy. To this end, we employed physiologically relevant HBV infection models of primary human hepatocytes (PHHs) and differentiated HepaRG cells in conjunction with pharmacologic PLK1 inhibitors, small interfering RNA (siRNA)-mediated knockdown, and overexpression of constitutively active PLK1 (PLK1CA ). In addition, a humanized liver Fah-/- /Rag2-/- /Il2rg-/- (FRG) mouse model was used to determine the antiviral effect of PLK1 inhibitor BI-2536 on HBV infection in vivo. Finally, in vitro PLK1 kinase assays and site-directed mutagenesis were employed to demonstrate that HBV core protein (HBc) is a PLK1 substrate. We demonstrated that HBV infection activated cellular PLK1 in PHHs and differentiated HepaRG cells. PLK1 inhibition by BI-2536 or siRNA-mediated knockdown suppressed HBV DNA biosynthesis, whereas overexpression of PLK1CA increased it, suggesting that the PLK1 effects on viral biosynthesis are specific and that PLK1 is a proviral cellular factor. Significantly, BI-2536 administration to HBV-infected humanized liver FRG mice strongly inhibited HBV infection, validating PLK1 as an antiviral target in vivo. The proviral action of PLK1 is associated with the biogenesis of the nucleocapsid, as BI-2536 leads to its decreased intracellular formation/accumulation. In this respect, our studies identified HBc as a PLK1 substrate in vitro, and mapped PLK1 phosphorylation sites on this protein. CONCLUSION: PLK1 is a proviral host factor that could be envisaged as a target for combined antiviral and antitumoral strategies against HBV infection and HBV-mediated carcinogenesis. (Hepatology 2017;66:1750-1765).
引用
- Diab A, Foca A, Fusil F, et al. Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication. Hepatology. 2017. PMID: 28445592. doi:10.1002/hep.29236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。